Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients
EGFR-mutant non-small cell lung cancer is routinely treated with EGFR inhibitors, although resistance inevitably develops. Here, the authors sequence circulating tumour DNA and show that resistance to the third-generation inhibitor rociletinib is heterogeneous and recurrently involves somatic altera...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Nature Portfolio
2016
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/e467721976a7414699480c405cfa9845 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:e467721976a7414699480c405cfa9845 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:e467721976a7414699480c405cfa98452021-12-02T16:49:57ZCirculating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients10.1038/ncomms118152041-1723https://doaj.org/article/e467721976a7414699480c405cfa98452016-06-01T00:00:00Zhttps://doi.org/10.1038/ncomms11815https://doaj.org/toc/2041-1723EGFR-mutant non-small cell lung cancer is routinely treated with EGFR inhibitors, although resistance inevitably develops. Here, the authors sequence circulating tumour DNA and show that resistance to the third-generation inhibitor rociletinib is heterogeneous and recurrently involves somatic alterations of MET, EGFR, PIK3CA, ERRB2, and KRAS.Jacob J. ChabonAndrew D. SimmonsAlexander F. LovejoyMohammad S. EsfahaniAaron M. NewmanHenry J. HaringsmaDavid M. KurtzHenning StehrFlorian SchererChris A. KarlovichThomas C. HardingKathleen A. DurkinGregory A. OttersonW. Thomas PurcellD. Ross CamidgeJonathan W. GoldmanLecia V. SequistZofia PiotrowskaHeather A. WakeleeJoel W. NealAsh A. AlizadehMaximilian DiehnNature PortfolioarticleScienceQENNature Communications, Vol 7, Iss 1, Pp 1-15 (2016) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Science Q |
| spellingShingle |
Science Q Jacob J. Chabon Andrew D. Simmons Alexander F. Lovejoy Mohammad S. Esfahani Aaron M. Newman Henry J. Haringsma David M. Kurtz Henning Stehr Florian Scherer Chris A. Karlovich Thomas C. Harding Kathleen A. Durkin Gregory A. Otterson W. Thomas Purcell D. Ross Camidge Jonathan W. Goldman Lecia V. Sequist Zofia Piotrowska Heather A. Wakelee Joel W. Neal Ash A. Alizadeh Maximilian Diehn Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients |
| description |
EGFR-mutant non-small cell lung cancer is routinely treated with EGFR inhibitors, although resistance inevitably develops. Here, the authors sequence circulating tumour DNA and show that resistance to the third-generation inhibitor rociletinib is heterogeneous and recurrently involves somatic alterations of MET, EGFR, PIK3CA, ERRB2, and KRAS. |
| format |
article |
| author |
Jacob J. Chabon Andrew D. Simmons Alexander F. Lovejoy Mohammad S. Esfahani Aaron M. Newman Henry J. Haringsma David M. Kurtz Henning Stehr Florian Scherer Chris A. Karlovich Thomas C. Harding Kathleen A. Durkin Gregory A. Otterson W. Thomas Purcell D. Ross Camidge Jonathan W. Goldman Lecia V. Sequist Zofia Piotrowska Heather A. Wakelee Joel W. Neal Ash A. Alizadeh Maximilian Diehn |
| author_facet |
Jacob J. Chabon Andrew D. Simmons Alexander F. Lovejoy Mohammad S. Esfahani Aaron M. Newman Henry J. Haringsma David M. Kurtz Henning Stehr Florian Scherer Chris A. Karlovich Thomas C. Harding Kathleen A. Durkin Gregory A. Otterson W. Thomas Purcell D. Ross Camidge Jonathan W. Goldman Lecia V. Sequist Zofia Piotrowska Heather A. Wakelee Joel W. Neal Ash A. Alizadeh Maximilian Diehn |
| author_sort |
Jacob J. Chabon |
| title |
Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients |
| title_short |
Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients |
| title_full |
Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients |
| title_fullStr |
Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients |
| title_full_unstemmed |
Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients |
| title_sort |
circulating tumour dna profiling reveals heterogeneity of egfr inhibitor resistance mechanisms in lung cancer patients |
| publisher |
Nature Portfolio |
| publishDate |
2016 |
| url |
https://doaj.org/article/e467721976a7414699480c405cfa9845 |
| work_keys_str_mv |
AT jacobjchabon circulatingtumourdnaprofilingrevealsheterogeneityofegfrinhibitorresistancemechanismsinlungcancerpatients AT andrewdsimmons circulatingtumourdnaprofilingrevealsheterogeneityofegfrinhibitorresistancemechanismsinlungcancerpatients AT alexanderflovejoy circulatingtumourdnaprofilingrevealsheterogeneityofegfrinhibitorresistancemechanismsinlungcancerpatients AT mohammadsesfahani circulatingtumourdnaprofilingrevealsheterogeneityofegfrinhibitorresistancemechanismsinlungcancerpatients AT aaronmnewman circulatingtumourdnaprofilingrevealsheterogeneityofegfrinhibitorresistancemechanismsinlungcancerpatients AT henryjharingsma circulatingtumourdnaprofilingrevealsheterogeneityofegfrinhibitorresistancemechanismsinlungcancerpatients AT davidmkurtz circulatingtumourdnaprofilingrevealsheterogeneityofegfrinhibitorresistancemechanismsinlungcancerpatients AT henningstehr circulatingtumourdnaprofilingrevealsheterogeneityofegfrinhibitorresistancemechanismsinlungcancerpatients AT florianscherer circulatingtumourdnaprofilingrevealsheterogeneityofegfrinhibitorresistancemechanismsinlungcancerpatients AT chrisakarlovich circulatingtumourdnaprofilingrevealsheterogeneityofegfrinhibitorresistancemechanismsinlungcancerpatients AT thomascharding circulatingtumourdnaprofilingrevealsheterogeneityofegfrinhibitorresistancemechanismsinlungcancerpatients AT kathleenadurkin circulatingtumourdnaprofilingrevealsheterogeneityofegfrinhibitorresistancemechanismsinlungcancerpatients AT gregoryaotterson circulatingtumourdnaprofilingrevealsheterogeneityofegfrinhibitorresistancemechanismsinlungcancerpatients AT wthomaspurcell circulatingtumourdnaprofilingrevealsheterogeneityofegfrinhibitorresistancemechanismsinlungcancerpatients AT drosscamidge circulatingtumourdnaprofilingrevealsheterogeneityofegfrinhibitorresistancemechanismsinlungcancerpatients AT jonathanwgoldman circulatingtumourdnaprofilingrevealsheterogeneityofegfrinhibitorresistancemechanismsinlungcancerpatients AT leciavsequist circulatingtumourdnaprofilingrevealsheterogeneityofegfrinhibitorresistancemechanismsinlungcancerpatients AT zofiapiotrowska circulatingtumourdnaprofilingrevealsheterogeneityofegfrinhibitorresistancemechanismsinlungcancerpatients AT heatherawakelee circulatingtumourdnaprofilingrevealsheterogeneityofegfrinhibitorresistancemechanismsinlungcancerpatients AT joelwneal circulatingtumourdnaprofilingrevealsheterogeneityofegfrinhibitorresistancemechanismsinlungcancerpatients AT ashaalizadeh circulatingtumourdnaprofilingrevealsheterogeneityofegfrinhibitorresistancemechanismsinlungcancerpatients AT maximiliandiehn circulatingtumourdnaprofilingrevealsheterogeneityofegfrinhibitorresistancemechanismsinlungcancerpatients |
| _version_ |
1718383190204219392 |